DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
Haluska P, Worden F, Olmos D. et al.
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
Cancer Chemother Pharmacol 2010;
65: 765-773
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.